Gram Research analysis of a 2026 study of 135,216 adults with type 2 diabetes found that tirzepatide was linked to a 12% lower rate of nutritional deficiency anemia than other GLP-1 medications over one year. The difference was driven mainly by iron deficiency anemia, which was 13% lower with tirzepatide.

According to research reviewed by Gram, adults with type 2 diabetes and obesity who started tirzepatide were less likely to be diagnosed with a nutritional anemia than those who started other GLP-1 medications. Nutritional anemia occurs when the body does not have enough iron, vitamin B12, or folate to make healthy red blood cells. The study used electronic health records from the TriNetX database and compared 67,608 matched patients in each group over one year. Overall, 2.13% of tirzepatide users were diagnosed with this condition, compared with 2.84% of GLP-1 users. The difference came mostly from iron deficiency anemia, which was about 13% less likely with tirzepatide. Results for vitamin B12 and folate deficiency were unclear. Because this was an observational study, it cannot prove the drug caused the difference, so people on these medications should keep up with routine blood tests and nutrition care.

Key Statistics

A 2026 cohort study of 135,216 adults with type 2 diabetes and overweight or obesity found that 2.13% of tirzepatide users developed nutritional deficiency anemia within one year, compared with 2.84% of GLP-1 receptor agonist users.

In the same 2026 cohort study, tirzepatide initiation was associated with a hazard ratio of 0.87 (95% confidence interval 0.81 to 0.93) for iron deficiency anemia compared with other GLP-1 medications.

The 2026 TriNetX-based cohort study found that vitamin B12 deficiency anemia (hazard ratio 1.07) and folate deficiency anemia (hazard ratio 0.98) showed inconclusive results when comparing tirzepatide with GLP-1 medications.

The Quick Take

  • What they studied: Researchers wanted to know whether tirzepatide, a newer diabetes and weight-loss medication, is less likely than older GLP-1 medications to cause a shortage of iron, vitamin B12, or folate that leads to anemia.
  • Who participated: The study included adults with type 2 diabetes and overweight or obesity who started either tirzepatide or another GLP-1 medication between 2022 and 2026. People who had recently used these drugs, had type 1 diabetes, had nutritional anemia already, or had weight-loss surgery were excluded. After matching, each group contained 67,608 people.
  • Key finding: Within one year, 2.13% of tirzepatide users developed nutritional anemia compared with 2.84% of other GLP-1 users, a risk about 12% lower. Iron deficiency anemia was about 13% less likely with tirzepatide. That works out to roughly 7 fewer cases per 1,000 people over a year, and the results for vitamin B12 and folate were inconclusive.
  • What it means for you: If you take tirzepatide, this study offers some reassurance that it may carry a lower risk of iron-related anemia than some other diabetes medications. It does not mean the risk is zero, so talk with your doctor about blood tests, especially if you feel unusually tired, weak, or short of breath.

The Research Details

This was a retrospective cohort study, meaning researchers looked back at existing medical records instead of assigning people to treatments themselves. They used the TriNetX database, which contains anonymized health records from many healthcare organizations.

To make the two groups comparable, the researchers used a statistical method called propensity score matching. This pairs each tirzepatide user with a GLP-1 user who had similar age, health conditions, and other traits, which helps reduce the chance that differences between the groups come from something other than the medication.

The researchers then tracked each person from the first day of treatment through 365 days and counted new diagnoses of iron, vitamin B12, or folate deficiency anemia. They reported results as hazard ratios, which compare how quickly the condition appeared in one group versus the other. A value below 1 means the condition showed up less often in the tirzepatide group.

Patients usually take these medications for years, so even small differences in side effects can matter. Using large, real-world records allows researchers to see how drugs perform in everyday care, not just in tightly controlled trials. Matching the groups also makes the comparison fairer, although it cannot account for every difference between patients.

The study is large, with more than 130,000 people in the matched groups, and it was published in a peer-reviewed diabetes journal. Its main strength is the size of the comparison and the use of matching to balance patient characteristics. However, the data come from health records, which were not collected for research, so some diagnoses may have been missed or recorded inconsistently. The study also cannot fully rule out hidden differences between patients who received each drug. The sample size listed in the database summary (608) does not match the numbers in the abstract, so readers should check the full paper for the exact count.

What the Results Show

The main result was that nutritional deficiency anemia was diagnosed less often in people starting tirzepatide. Among tirzepatide users, 2.13% (1,440 people) developed this condition, compared with 2.84% (1,917 people) of GLP-1 users. The hazard ratio of 0.88, with a 95% confidence interval of 0.83 to 0.95, means the risk was about 12% lower in the tirzepatide group. The confidence interval not crossing 1 suggests this difference is unlikely to be due to chance alone.

The benefit appeared mainly for iron deficiency anemia. Tirzepatide users had a hazard ratio of 0.87 (0.81 to 0.93), which indicates about 13% lower risk. Iron is one of the most common nutrients people lack, so this finding stands out.

For vitamin B12 deficiency anemia (hazard ratio 1.07, range 0.83 to 1.38) and folate deficiency anemia (hazard ratio 0.98, range 0.56 to 1.71), the results were inconclusive. The ranges for these outcomes are wide and include both possible benefit and possible harm, so the data cannot point in either direction. These conditions were also much less common, so there were fewer cases to analyze.

In practical terms, the absolute difference is small. The gap of about 0.7 percentage points means roughly 7 fewer people per 1,000 would be diagnosed with this type of anemia over one year. Still, for people taking these drugs long term, a small reduction in a common side effect may be meaningful.

The study focused on diagnosed cases, so it did not measure how much iron, B12, or folate people had in their blood or diet. Because the analysis looked at diagnoses, it may reflect how often doctors ordered blood tests and identified anemia, as well as what happened to patients. The secondary outcomes for B12 and folate did not show a clear pattern, suggesting that the main benefit may be specific to iron.

Some GLP-1 and related medications have been linked to nutrient problems, partly because reduced appetite and food intake can lead to lower intake of iron, B12, and folate. Research on this specific question has been limited, which makes this comparison useful. The finding that tirzepatide was linked to less iron-related anemia fits with the idea that drug-specific effects may matter, but more studies are needed to confirm it across different populations and longer time periods.

Because this was an observational study, it can show an association but cannot prove that tirzepatide caused the lower rate of anemia. Other differences between patients, such as diet, income, or how closely they were monitored, may have influenced the results. The study followed people for only one year, so it does not show what happens over many years. Health records also depend on whether doctors tested for anemia and recorded it, so differences in testing could affect the numbers. The results for vitamin B12 and folate were inconclusive, and the study does not explain why the iron finding occurred.

The Bottom Line

Based on this study, tirzepatide appears to be associated with a modestly lower risk of iron deficiency anemia than other GLP-1 medications. Confidence in this finding is moderate because it comes from a large real-world study, but it has not been confirmed by a randomized trial designed to test this question. No firm conclusions can be drawn about vitamin B12 or folate. Anyone taking these medications should keep up with routine care and discuss nutrition and blood testing with their healthcare provider.

This research is most relevant to adults with type 2 diabetes and overweight or obesity who are considering or currently taking tirzepatide or another GLP-1 medication. Clinicians who prescribe these drugs may also find it useful when planning monitoring. People with type 1 diabetes, those who have had weight-loss surgery, or those already diagnosed with anemia were not part of this study, so these findings may not apply to them. Anyone should speak with a doctor before changing medication.

The study looked at outcomes over one year, so that is the timeframe the findings describe. Changes in nutrient levels can take weeks to months to show up in blood tests, and anemia usually develops gradually. Benefits from a lower risk of anemia would not be expected to appear quickly, and the difference reported in this study is modest, so people should not expect dramatic changes.

Frequently Asked Questions

Does tirzepatide cause anemia?

A 2026 cohort study of 135,216 adults found that tirzepatide was not linked to higher anemia risk. Nutritional anemia occurred in 2.13% of tirzepatide users versus 2.84% of other GLP-1 users within one year, though the study cannot prove cause and effect.

Is tirzepatide better than other GLP-1 drugs for iron levels?

A large 2026 study suggests tirzepatide may be linked to a lower risk of iron deficiency anemia. Iron deficiency anemia had a hazard ratio of 0.87 compared with other GLP-1 medications, meaning about 13% lower risk over one year in observational data.

What should I watch for if I take tirzepatide?

Watch for persistent tiredness, weakness, dizziness, pale skin, or shortness of breath. Research suggests routine blood tests can catch anemia early, so ask your doctor how often your hemoglobin and iron, B12, and folate levels should be checked.

How common is nutritional anemia in people taking diabetes weight-loss drugs?

In a 2026 study of adults with type 2 diabetes and obesity, about 2 to 3 out of every 100 people developed nutritional deficiency anemia within a year. The rate was 2.13% for tirzepatide and 2.84% for other GLP-1 medications.

Want to Apply This Research?

  • Log your medication start date and dosage, and record any fatigue, dizziness, or shortness of breath on a 1 to 5 scale each week. Also track your scheduled blood test dates, including hemoglobin and iron-related results, so you can see trends over time.
  • Use the app to log iron-rich foods such as lean meat, beans, lentils, fortified cereals, and leafy greens each day, and set a reminder to eat vitamin C sources alongside them to help absorption. If your diet is limited because of reduced appetite, flag this in the app so you can review it with your care team.
  • Review your logged symptoms and food intake monthly, and bring the summary to your medical appointments. Ask your doctor how often blood counts and iron, B12, and folate levels should be checked while you are on the medication. Over time, compare your results and symptoms to spot any changes early.

This article summarizes an observational study of medical records and cannot prove that a medication caused any health outcome. It is not medical advice. Do not start, stop, or change tirzepatide or any other medication without talking to your doctor, and ask a healthcare professional about blood tests and nutrition if you have symptoms or concerns.

This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.

Source: Tirzepatide and risk of nutritional deficiency anemia compared with GLP-1 receptor agonists in adults with type 2 diabetes and overweight or obesity. , Diabetes research and clinical practice (2026). PubMed 43044770 | DOI
Topics
tirzepatide GLP-1 medications iron deficiency anemia nutritional anemia type 2 diabetes weight loss medication vitamin B12 deficiency folate deficiency